Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Myriad Genetics
June 01, 2018
Snippet roundup: Fibrogen's Japanese hit and Madrigal's smash in Nash
March 16, 2018
Snippet roundup: J&J shrinks, while Vernalis vanishes altogether
November 03, 2017
GeneSight trial miss leaves Myriad depressed
January 09, 2017
A quiet year for mid-size medtech
December 20, 2016
Early visit from Santa puts the heat on Clovis
October 26, 2016
Lynparza shows that Parp competitors have it all to do
October 14, 2016
Snippet roundup: Biomarin boosted, Synairgen stung
October 12, 2016
Esmo event analyser – Tesaro tops the risers while Bristol-Myers is battered
October 09, 2016
Esmo – Tesaro enjoys a ta-dah moment
August 12, 2016
Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys
August 24, 2015
Biomarin goes for pragmatism as the markets dip
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 09, 2020
What makes a great year for takeovers?
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
December 19, 2019
Gene therapy clinical holds take centre stage
December 20, 2019
Plenty of choice remains for buyers of gene therapy
October 14, 2019
Uncovering biopharma’s hidden treasures
